ArticleNature2022
Signatures of copy number alterations in human cancer.
Abstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 328 papers.
0numbers the graph read from it
0cells of the map it votes in
328citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
328 citing papers in PubMed.
- Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.Nature medicine · 2026Trial
- Trial
- Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).Journal for immunotherapy of cancer · 2025Trial
- Article
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Unraveling the lexicon of complex mutational phenomena in human cancers.Nature cancer · 2026Review
- FFPE-CUTAC: A Single Assay, Multiple Layers.bioRxiv : the preprint server for biology · 2026Article
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Benchmarking copy number alteration inference methods for spatial transcriptomics.Nature communications · 2026Article
- Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency.Experimental & molecular medicine · 2026Article
- Article
- Identifying multigenic modules under selection in the tumor genome.Bioinformatics (Oxford, England) · 2026Article
- Origins and consequences of oncogenic 3D chromatin remodelling.Nature reviews. Cancer · 2026Review
- Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer.International journal of molecular sciences · 2026Article
- Sellar region neurocytomas exhibit a CIMP and neuroendocrine-like epigenetic signature distinct from other intra-axial neurocytomas.Acta neuropathologica · 2026Article
- scAmp enables focal gene amplification analysis from single-cell data.Nature communications · 2026Article
- Examining the role of extrachromosomal DNA in lung cancer.Journal of the National Cancer Institute · 2026Article
- A medium throughput approach for single cell copy number variation sequencing towards efficient application in clinics.Journal of advanced research · 2026Article
- ClairS: a deep-learning method for long-read tumor-normal pair somatic small variant calling.Nature methods · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
268 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Christopher D SteeleResearch Department of Pathology, Cancer Institute, University College London, London, UK.
Ammal AbbasiDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
S M Ashiqul IslamDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Amy L BowesResearch Department of Pathology, Cancer Institute, University College London, London, UK.
Azhar KhandekarDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.
Kerstin HaaseCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-0944-5618
Shadi Hames-FathiResearch Department of Pathology, Cancer Institute, University College London, London, UK.
Dolapo AjayiResearch Department of Pathology, Cancer Institute, University College London, London, UK.
Annelien VerfaillieCancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Pawan DhamiCRUK-UCL Cancer Institute Translational Technology Platform (Genomics), London, UK.
Alex McLatchieCRUK-UCL Cancer Institute Translational Technology Platform (Genomics), London, UK.
Matt LechnerResearch Department of Oncology, UCL Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-7123-0773
Nicholas LightGenetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Adam ShlienInstitute of Medical Science, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-0368-5370
David MalkinGenetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-5752-9763
Andrew FeberTranslational Epigenetics, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
Paula ProszekTranslational Epigenetics, Division of Molecular Pathology, Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-0780-6790
Tom LesluyesCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2251-5884
Fredrik MertensDivision of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-6278-5232
Adrienne M FlanaganResearch Department of Pathology, Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0002-2832-1303
Maxime TarabichiCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1635-2348
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0292-1949
Ludmil B Alexandrov *Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA. L2alexandrov@health.ucsd.edu.
Nischalan Pillay *Research Department of Pathology, Cancer Institute, University College London, London, UK. N.pillay@ucl.ac.uk.ORCID http://orcid.org/0000-0003-0579-4105
Funding
Detecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4MMutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet RadiationR01ES030993 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUDSON, LAURIE G, LIU, KE JIAN · 2020 to 2024
$2.5MCancer Research UK 18387Medical Research Council MR/L016311/1NIEHS NIH HHS R01 ES030993NIEHS NIH HHS R01 ES032547Wellcome Trust FC001202
Abstract
Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-related processes of replication stress, mitotic errors, spindle multipolarity and breakage-fusion-bridge cycles, among others, which may lead to chromosomal instability and aneuploidy
Indexed as
DNA Copy Number VariationsDNA Mutational AnalysisNeoplasmsAneuploidyChromothripsisExome SequencingHaploidyHomologous RecombinationHumansLoss of HeterozygosityMutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.